Tamsulosin Sales Ranking in 2020
Tamsulosin, sold as Flomax and generics for benign prostatic hyperplasia, ranked 88th among top drugs by U.S. retail sales in 2020, with $1.18 billion in total sales.[1][2]
How Tamsulosin Sales Compared to Other Top Drugs That Year
It trailed alpha-blockers like finasteride (Proscar, #62 at $1.57B) but outpaced other urology drugs such as sildenafil (Viagra, #124 at $802M). Top sellers included semaglutide (Ozempic, #1 at $7.9B) and apixaban (Eliquis, #2 at $6.8B), driven by diabetes and anticoagulant demand amid COVID-19.[1][3]
What Dropped Tamsulosin's Rank from Prior Years
Generic entry in 2009 eroded branded Flomax sales from a 2007 peak of $1.9B (#8 overall). By 2020, all sales were generic, with volume steady at ~40 million prescriptions but average price per script falling to $25 from $150 pre-generic.[2][4] This placed it mid-pack among mature generics.
Sales Trends into 2021 and Beyond
U.S. sales dipped to $1.05B (#102) in 2021 as competition grew from silodosin (Rapaflo) and combination therapies like dutasteride/tamsulosin (Jalyn).[1] Global sales held at ~$1.5B, mostly U.S.-driven, with flat growth projected through 2025 due to market saturation.[5]
Key Players and Generic Competition
Astellas Pharma originated Flomax; top 2020 generic makers included Mylan (now Viatris), Teva, and Sandoz, sharing 80% of scripts. No major patents remained active post-2014 pediatric exclusivity end.[6]
[1]: IQVIA National Prescription Audit, 2020 U.S. Drug Sales Report
[2]: DrugPatentWatch.com - Tamsulosin Sales Data
[3]: FDA Orange Book - Tamsulosin Approvals
[4]: IMS Health via Statista - Top 100 U.S. Drugs 2020
[5]: EvaluatePharma World Preview 2021
[6]: DrugPatentWatch.com - Flomax Patent Expiry Timeline